>We thought initially the ATRYN market in Europe is just 'proof of concept' but it obviously has ballooned to a lucrative proposition especially on the pricing side.<
The HD indication in Europe is still essentially a proof of concept for GTC’s technology. Even at the price premium to plasma-derived AT, the sales for HD will be relatively small and Leo gets most of the profit.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.